Delivery Order SPE2DB20D1100-SPE2DB25FE0HU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of UBRELVY 100 MG tablets in unit dose packaging (10 tablets per unit). This competitively awarded, firm fixed-price delivery order has a ceiling value of $6,583.77 and an ultimate completion date of September 17, 2025. The contract is issued without a set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order contract for UBRELVY 100 mg tablets (16-count unit dose packages) on September 9, 2025, with a contract ceiling value of $1,252.24 and ultimate completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement. The work is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of UBRELVY 50 mg tablets in unit dose packaging (10 count). This competitively awarded, non-set-aside delivery order has a ceiling value of $18,553.61 with a firm fixed price structure and an ultimate completion date of September 22, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (16 count) with a contract ceiling value of $4,734.66. This is a firm fixed-price delivery order with an ultimate completion date of August 7, 2025, representing a competitively awarded contract with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,856.58 to AmerisourceBergen Drug Corp for UBRELVY 50 MG tablets (10 unit doses) on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract under the company's broader pharmaceutical supply agreement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of UBRELVY 50 mg tablets (10-count unit dose packaging) with a ceiling value of $4,919.80 and an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packages of 10, with a contract ceiling value of $2,361.15 and an ultimate completion date of June 3, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (100-count unit dose packages) valued at $32,471.79 under a firm fixed-price contract type. The order, issued on September 15, 2025, with an ultimate completion date of September 16, 2025, represents a non-competitive, non-set-aside award to support federal medical supply needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0HUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packs of 10, with a ceiling value of $8,505.23. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and is well-positioned to fulfill this requirement through its established relationship with the Defense Logistics Agency. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. That prime IDC vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. UBRELVY is a migraine treatment medication, consistent with the company's portfolio of specialty pharmaceuticals and brand-name drugs supplied to the Defense Health Agency and other federal healthcare systems. The short completion timeframe reflects the urgent medical supply needs typical of federal pharmaceutical procurement operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 9/17/25 |